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Definitions 
Pulmonary hypertension (PH) is defined as elevated pulmonary artery pressure (PAP) 
secondary to various pathophysiologies causing cor pulmonale and eventually right 
sided heart failure. The WHO classification of PH is based on similarities in 
pathophysiologic mechanisms (see table).  
Pulmonary arterial hypertension (PAH) is a progressive vasoproliferative condition 
characterized by increased pulmonary artery pressure. Patients with PAH by definition 
do not have significant left heart disease, lung disease or chronic thromboembolic 
disease. Specific hemodynamic criteria include systolic PAP >30 mmHg, diastolic PAP 
>20 mmHg, mean PAP >25 mmHg, pulmonary capillary wedge pressure <15 mmHg. 
Idiopathic PAH (formerly primary PH or PPH) is diagnosed, when no underlying cause 
for PH and characteristic histological abnormalities in small pulmonary arteries  can be 
identified. Histological abnormalities include intimal, medial and adventitial 
proliferation, plexogenic changes consisting of proliferating epithelial cells mixed with 
myofibroblasts and necrotizing arteritis. 
Cor pulmonale refers to right ventricular hypertrophy secondary to PH. 
 
Etiology and pathophysiology 
In simple terms, PH reflects an obstruction to blood flow from the right ventricle to the 
left ventricle. In PAH (table, group 1), the underlying vascular injury is thought to be a 
final common response to various inciting factors coupled with genetic susceptibility. 
Eliciting factors may be mechanical (overperfusion), drugs (experimentally inducible 
with appetite suppressants), toxins, infections, and genetically determined susceptibility 
to such injuries. Thrombosis elicited by diseased vessel walls may complicate PAH.  
Then, PH is a common complication of different cardiac and extracardiac diseases 
and results from two main mechanisms: increased left atrial pressure and increased 
pulmonary vascular resistance (table, group 2-4). Specific causes are  
Cardiac: Pulmonary venous hypertension due to increased left atrial pressure in left sided 
heart disease, most common in advanced chronic degenerative mitral valve disease, also 
in dilated cardiomyopathy; cor triatriatum sinister, mitral stenosis (table, group 2). 
Pulmonary parenchymal disease: Pulmonary fibrosis; ARDS; Hypoxic vasoconstriction: 
Chronic obstructive lower airway disease (bronchitis, emphysema); chronic obstructive 
upper airway disease; high altitude hypoxia (table, group 3). 
Occlusion of the pulmonary vascular bed: Pulmonary thrombosis and / or embolism 
(PTE) associated with various systemic or pulmonary diseases; Parasites (D. immitis, A. 
vasorum) (table, group 4).  
Combination of mechanisms. 
 
Table: Classification of pulmonary hypertension* 
 
Group 1. Pulmonary arterial hypertension (PAH) 
Idiopathic (formerly primary PH, PPH) 
Associated with congenital systemic-to-pulmonic shunts 
Persistent pulmonary hypertension of the newborn 
Associated with drugs, toxins, inflammatory conditions 
 
Group 2. Pulmonary hypertension associated with left heart disease 
Left ventricular or atrial disease 
Left-sided valvular disease 
 
Group 3. Pulmonary hypertension associated with respiratory disease and/or hypoxemia 
Interstitial lung disease, e.g. pulmonary fibrosis 
Chronic upper airway obstruction 
Chronic exposure to high altitude 
 
Group 4. Pulmonary hypertension due to thromboembolic disease 
Primary cardio-vascular lesion, e.g. D. immitis, A. vasorum 
Medical condition predisposing to pulmonary thromboembolism 
 
Group 5. Miscellaneous 
 
*source: WHO classification, Chin and Rubin, 2008, modified and adapted for dog 
 
Diagnosis 
Thoracic radiographs for signs of PH as well as potential underlying cause of PH.  
Dorsoventral view particularly helpful to document right ventricular and main 
pulmonary artery enlargement. Peripheral pulmonary vasculature may be tortuous and 
enlarged. Left atrium is enlarged and pulmonary veins are congested with underlying 
left atrial, ventricular or mitral valve disease. Signs of underlying bronchial, interstitial 
or alveolar pulmonary disease may be evident. 
Echocardiogram, dual role: Rule in or out causes of PH, including acquired left 
ventricular heart disease (mitral endocardiosis, dilated cardiomyopathy) and congenital 
cardiovascular shunt. Confirmation of PH qualitatively and quantitatively: 
Qualitatively: characteristic two-dimensional and M-mode findings in moderate to 
severe PH are dilation of right ventricle and atrium, thickening of right ventricular wall 
and papillary muscles, paradoxical septal motion, and decreased left ventricular 
chamber size. 
Quantitatively: Doppler examination is the most useful noninvasive clinical tool to 
confirm and quantitate severity of PH. Systolic: velocity of tricuspid regurgitation (TR) 
correlates to right ventricular systolic pressure, and therefore, barring pulmonic stenosis, 
to systolic PAP. The modified Bernoulli equation allows Doppler-derived blood flow 
velocities to be used for estimating intracardiac pressures: PG = 4   Vmax
2
. Applied to the 
right ventricle, TR-PG is the peak pressure gradient between right ventricle and right 
atrium, in mmHg, and Vmax is the peak velocity of tricuspid regurgitation (TR), in m/sec. 
Assuming that right atrial pressure approximates 0 mmHg during ventricular systole, the 
TR-PG equals systolic right ventricular pressure, and if  >30 mmHg (Vmax >2.8 m/s) 
indicates systolic PH. Diastolic PAP is calculated with Doppler quantification of 
pulmonary valve insufficiency (PI); PH is considered to be present when enddiastolic PI-
PG is >20 mmHg  (Vmax >2.2 m/s). 
 
Advanced or confirmatory testing 
Contrast ultrasound (microbubbles) of the heart and descending aorta to rule out 
cardiovascular right-to-left shunt. Shunt is also possible in congenital pulmonary 
arteriovenous fistula or in acquired pulmonary arteriovenous shunting, like in A. 
vasorum infection; in this case, bubbles will take at least 3 cardiac cycles from their 
appearance in the right atrium till their appearance in the left atrium. 
Right-sided cardiac catheterization for invasive measurement of pulmonary wedge 
pressure as an estimate of left atrial pressure, and systolic and diastolic pulmonary 
artery pressure. 
Pulmonary CT to identify / rule-out parenchymal disease and Angio-CT for PTE. 
Pulmonary ventilation-perfusion scintigraphy to rule out PTE 
Pulmonary histopathologic evaluation to confirm PAH 
 Therapeutic goals 
General:  
PH of any genesis: lower PAP (see below).  
PH of any genesis with signs referable to hypoxia: improve oxygenation. 
PH with known pathogenesis and treatable cause: focus should be to correct/improve  
underlying disease, e.g. left heart disease; PTE, heartworms. 
Specific to lower PAP: 
There is no randomized trial documenting efficacy of medical treatment in naturally 
occurring PH in dogs, however, all the following treatment consideration may 
beneficially lower PAP: 
Oxygen, cage, nasal or mask. 
Amlodipine (Norvasc) in moderate PH, starting at 0.05 mg/kg PO q 24h and titrating 
dose based on response and BP (avoid hypotension) 
Sildenafil (Viagra) in severe PH, 2–3 mg/kg PO q 8-12h. Improves clinical condition in 
the absence of remarkable effects on PAP. 
Pimobendan (Vetmedin), 0.2-0.6 mg/kg div q 12h. 
Oral L-Arginine, 100 mg/kg q8h (dosage from one human study).  
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